NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 58 filers reported holding NEUROCRINE BIOSCIENCES INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $601,000 | -2.3% | 400 | 0.0% | 0.01% | 0.0% |
Q4 2019 | $615,000 | +11.6% | 400 | 0.0% | 0.01% | 0.0% |
Q3 2019 | $551,000 | +4.6% | 400 | 0.0% | 0.01% | 0.0% |
Q2 2019 | $527,000 | +93.0% | 400 | +100.0% | 0.01% | +133.3% |
Q1 2019 | $273,000 | +15.7% | 200 | 0.0% | 0.00% | -25.0% |
Q4 2018 | $236,000 | – | 200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SSI INVESTMENT MANAGEMENT LLC | 7,440,000 | $10,058,000 | 0.84% |
SHENKMAN CAPITAL MANAGEMENT INC | 4,121,000 | $5,579,000 | 0.72% |
Baker Brothers Advisors | 53,270,000 | $71,994,000 | 0.46% |
LINDEN ADVISORS LP | 11,675,000 | $15,814,000 | 0.36% |
ADVENT CAPITAL MANAGEMENT /DE/ | 11,558,000 | $15,650,000 | 0.34% |
AQR Arbitrage LLC | 20,000,000 | $27,077,000 | 0.34% |
CSS LLC/IL | 3,455,000 | $4,675,000 | 0.28% |
RWC Asset Management LLP | 4,000,000 | $5,396,000 | 0.25% |
MACKAY SHIELDS LLC | 21,460,000 | $29,043,000 | 0.21% |
Calamos Advisors LLC | 24,105,000 | $32,660,000 | 0.20% |